Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria:

   1. Have histologically proven, newly diagnosed glioblastoma multiforme

   2. Age ≥ 18 years and < 70 years

   3. Have an ECOG performance score of 0, 1, or 2, or KPS ≥ 70

   4. Have adequate bone marrow function , liver function, and kidney function before
   starting therapy

   5. Begin study therapy no more than 6 weeks after surgery or biopsy

   6. Subjects that have had surgery must have an MRI ≤ 72 hours after surgery

Exclusion Criteria:

   1. Have a carmustine implant (e.g., Gliadel® Wafer)

   2. Have uncontrolled hypertension (SBP > 140 mmHg or DBP > 90 mmHg for more than 1 week)

   3. Have a left ventricular ejection fraction below the lower limit of the reference range
   for the institution, as measured by multiple gated acquisition (MUGA) or
   echocardiogram (ECHO)

   4. Have Troponin-I or Troponin T at Screening visit elevated above the upper limit of the
   reference range of the local institution

   5. Have an increasing steroid requirement, indicative of a rapidly progressive disease

   6. Have evidence of new, active intra tumor hemorrhage ≥ CTCAE Grade 2

   7. Have had prior cranial radiotherapy

   8. Have history of stroke and/or transient ischemic attack within 2 years of screening

   9. Have history of cardiovascular disease (e.g., angina, myocardial infarction,
   congestive heart failure, etc.) within 2 years of screening

10. Be pregnant or breast feeding

11. Have a history of hypersensitivity reaction to Cremophor® EL

12. Have a history of hypersensitivity reaction or intolerance to temozolomide or
   dacarbazine (DTIC)